David Day and a lifetime of missed moments

David Day and a lifetime of missed moments

8 June 2018

“I couldn’t eat. Barely slept. I was the one to tell Dave it was all over. All Dave said was ‘my poor, poor babies’.”  Jenny, David’s wife.

When David lost his life last year, he was 33, with three daughters under six.

David Day was one of the 20% of people with advanced melanoma have primary resistance to new drugs with ‘super progression' and we need to find out why. 

The greatest challenge our clinicians currently face in treating melanoma is ‘super progression’.

Amid all our success stories, there is still a group of people with advanced melanoma for whom absolutely nothing works. About 20% of patients our medical oncologists see with advanced melanoma fall into this category.

Super progressors do not respond to existing treatments. Within a few short months, their disease progresses aggressively and relentlessly and we cannot save them.

David Day, was one such patient —a lovely young father with a wonderful family — who died last year.

The most agonising thing about patients like David is that at present, we just don’t know why they super progress.

Dr Inês Silva was part of the clinical team which treated David Day. She was studying at MIA as a Medical Oncology Fellow from Portugal. David had such a profound impact on Inês, that on completion of her Fellowship, she decided to stay on at MIA as a Research Scientist in an all-out attempt to find answers for super progressors.

Inês and the MIA research team collected blood and melanoma tissue samples from David during his treatment. They also collected similar samples from other advanced melanoma patients who have not responded to immunotherapy.

By studying the genomic profile and protein expression in each of these patients’ tumours, Ines and the MIA research team hope to understand why each drug failed to work, paving the way for new, and potentially life-saving therapies.

While there is some existing grant funding to cover her salary, a dedicated Research Scientist like Inês can’t do it alone.

We are relying on you and on the support of our donor community to collectively fund this research project including research assistants’ salaries, PhD student scholarship top-ups, equipment, and state-of-the-art research technologies such as DNA, RNA and cell sequencing. All are key to understanding and solving primary resistance and super progression.

David was a sweet, humble family man. He was a high-achiever, had forged an exceptional career as a computer engineer for Google and made a loving, happy life raising his three daughters Charlotte, 7, Emma, 5, and Annie, now 1, with his wife Jenny, his childhood sweetheart since Year 9.

Just before Christmas 2016, with Jenny heavily pregnant with little Annie, Dave found a lump under his left arm. He had Stage III melanoma. Half way through his treatment, David found another lump under his arm and a new tumour was discovered on his left hip. His melanoma had progressed to Stage IV.

In March 2017, David and Jenny were referred to Melanoma Institute Australia. He started on a clinical trial and at first, his scans looked promising.

After starting treatment, another painful melanoma appeared on David’s wrist. In the next three months, tumours sprang up in his spleen, lungs, pancreas, bones, under his skin —  with up to 30 more in his liver. Even though immune cells were present, David was super progressing.

As the months passed, David suffered extreme pain, liver damage, rapid weight loss, blurred vision and internal bleeding. The clinical team switched to chemotherapy as a last resort and Annie’s christening was pushed forward.

On 25 August 2017, Jenny had the worst imaginable task of explaining to her soul mate that nothing more could be done for him.

“I was the one to tell him it was over. All he could say was “My poor, poor babies”. My heart ached. I had lost 15kg over the past five months from the stress of the whole situation. My milk dried up and I couldn’t feed Annie. It ate away at me while I put on a brave face for Dave and the kids,” says Jenny.

Jenny has very generously shared her painful story in the hope that it will help raise funds to crack the riddle of super progression. 

Please give today to save someone you know from the ravages of melanoma in the future, and give them what David didn’t have- the opportunity to enjoy a lifetime of special moments with their loved ones.

Donate now

 

Founding father recognised for outstanding cancer care
15 Nov 2017

Founding father recognised for outstanding cancer care

Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.

Melanoma researchers shine at the State's premier cancer awards ceremony
03 Nov 2017

Melanoma researchers shine at the State's premier cancer awards ceremony

Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.

Enhancing melanoma treatment response through gut bacteria
03 Nov 2017

Enhancing melanoma treatment response through gut bacteria

New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.

Melanoma March is just around the corner!
01 Nov 2017

Melanoma March is just around the corner!

2018 will be bigger than ever, and a little bit different.

Comparing melanoma risk in similar populations across different latitudes
20 Oct 2017

Comparing melanoma risk in similar populations across different latitudes

MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.

Congratulations to our Conjoint Medical Directors
19 Oct 2017

Congratulations to our Conjoint Medical Directors

Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.

What causes melanoma in 90% of young Australians?
19 Oct 2017

What causes melanoma in 90% of young Australians?

New research shows potentially deadly UV damage can appear decades earlier than you think.

Early lymph node check is saving lives in melanoma patients
19 Oct 2017

Early lymph node check is saving lives in melanoma patients

Early lymph node check is saving lives in melanoma patients

Congratulations to Associate Professor Anne Cust
13 Oct 2017

Congratulations to Associate Professor Anne Cust

We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.

Smoking linked to increased risk of melanoma spreading
12 Oct 2017

Smoking linked to increased risk of melanoma spreading

New research has shown that melanoma patients who smoke have an increased risk of their disease progressing compared to patients who do not smoke.

Research boost to improve outcomes for melanoma patients
11 Oct 2017

Research boost to improve outcomes for melanoma patients

More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.

Highlights in melanoma research from ESMO
21 Sep 2017

Highlights in melanoma research from ESMO

The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.

Australian researchers stopping melanoma in its tracks
11 Sep 2017

Australian researchers stopping melanoma in its tracks

Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.

Virus-antibody combo shows promise for treating advanced melanoma
08 Sep 2017

Virus-antibody combo shows promise for treating advanced melanoma

A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.

It's time to outlaw sunburn on reality TV shows - enough is enough
31 Jul 2017

It's time to outlaw sunburn on reality TV shows - enough is enough

It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.

Identifying markers for optimal response
28 Jul 2017

Identifying markers for optimal response

Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?

Global Melanoma Research Report - July
20 Jul 2017

Global Melanoma Research Report - July

In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.

A day in the life of... Sarah Lane
14 Jul 2017

A day in the life of... Sarah Lane

Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process. 

Differentiating moles from melanoma
14 Jul 2017

Differentiating moles from melanoma

Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.

Introducing SunSense Sunscreen
11 Jul 2017

Introducing SunSense Sunscreen

We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.